Low Dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum Refractory Urothelial Carcinoma.
Rhonda L BittingJanet A ToozeMichael GoodmanDonald C VileJessica M BrownChristopher Y ThomasMorgan NeveMitra KooshkiSafoa AddoPierre L TriozziPurnima DubeyPublished in: Cancer research communications (2024)
The addition of low-dose paclitaxel to pembrolizumab is active and safe in platinum-refractory UC.